Copyright Reports & Markets. All rights reserved.

Global Oral Hypoglycemic Medications Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Oral Hypoglycemic Medications Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Biguanides
    • 1.3.3 Sulfonylureas
    • 1.3.4 Meglitinides
    • 1.3.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    • 1.3.6 SGLT2 Inhibitors
    • 1.3.7 Thiazolidinediones
    • 1.3.8 Alpha-Glucosidase Inhibitors
    • 1.3.9 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Oral Hypoglycemic Medications Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Other
  • 1.5 Global Oral Hypoglycemic Medications Market Size & Forecast
    • 1.5.1 Global Oral Hypoglycemic Medications Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Oral Hypoglycemic Medications Sales Quantity (2021-2032)
    • 1.5.3 Global Oral Hypoglycemic Medications Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Bayer
    • 2.1.1 Bayer Details
    • 2.1.2 Bayer Major Business
    • 2.1.3 Bayer Oral Hypoglycemic Medications Product and Services
    • 2.1.4 Bayer Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bayer Recent Developments/Updates
  • 2.2 Merck
    • 2.2.1 Merck Details
    • 2.2.2 Merck Major Business
    • 2.2.3 Merck Oral Hypoglycemic Medications Product and Services
    • 2.2.4 Merck Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Merck Recent Developments/Updates
  • 2.3 Novartis
    • 2.3.1 Novartis Details
    • 2.3.2 Novartis Major Business
    • 2.3.3 Novartis Oral Hypoglycemic Medications Product and Services
    • 2.3.4 Novartis Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Novartis Recent Developments/Updates
  • 2.4 Huadong Medicine
    • 2.4.1 Huadong Medicine Details
    • 2.4.2 Huadong Medicine Major Business
    • 2.4.3 Huadong Medicine Oral Hypoglycemic Medications Product and Services
    • 2.4.4 Huadong Medicine Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Huadong Medicine Recent Developments/Updates
  • 2.5 Sanofi
    • 2.5.1 Sanofi Details
    • 2.5.2 Sanofi Major Business
    • 2.5.3 Sanofi Oral Hypoglycemic Medications Product and Services
    • 2.5.4 Sanofi Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Sanofi Recent Developments/Updates
  • 2.6 Novo Nordisk
    • 2.6.1 Novo Nordisk Details
    • 2.6.2 Novo Nordisk Major Business
    • 2.6.3 Novo Nordisk Oral Hypoglycemic Medications Product and Services
    • 2.6.4 Novo Nordisk Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Novo Nordisk Recent Developments/Updates
  • 2.7 Servier
    • 2.7.1 Servier Details
    • 2.7.2 Servier Major Business
    • 2.7.3 Servier Oral Hypoglycemic Medications Product and Services
    • 2.7.4 Servier Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Servier Recent Developments/Updates
  • 2.8 Takeda Pharmaceutical
    • 2.8.1 Takeda Pharmaceutical Details
    • 2.8.2 Takeda Pharmaceutical Major Business
    • 2.8.3 Takeda Pharmaceutical Oral Hypoglycemic Medications Product and Services
    • 2.8.4 Takeda Pharmaceutical Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Takeda Pharmaceutical Recent Developments/Updates
  • 2.9 Luye Pharmaceutical
    • 2.9.1 Luye Pharmaceutical Details
    • 2.9.2 Luye Pharmaceutical Major Business
    • 2.9.3 Luye Pharmaceutical Oral Hypoglycemic Medications Product and Services
    • 2.9.4 Luye Pharmaceutical Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Luye Pharmaceutical Recent Developments/Updates
  • 2.10 Taiji Group
    • 2.10.1 Taiji Group Details
    • 2.10.2 Taiji Group Major Business
    • 2.10.3 Taiji Group Oral Hypoglycemic Medications Product and Services
    • 2.10.4 Taiji Group Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Taiji Group Recent Developments/Updates
  • 2.11 CR Double-Crane
    • 2.11.1 CR Double-Crane Details
    • 2.11.2 CR Double-Crane Major Business
    • 2.11.3 CR Double-Crane Oral Hypoglycemic Medications Product and Services
    • 2.11.4 CR Double-Crane Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 CR Double-Crane Recent Developments/Updates
  • 2.12 AstraZeneca
    • 2.12.1 AstraZeneca Details
    • 2.12.2 AstraZeneca Major Business
    • 2.12.3 AstraZeneca Oral Hypoglycemic Medications Product and Services
    • 2.12.4 AstraZeneca Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 AstraZeneca Recent Developments/Updates
  • 2.13 Boehringer Ingelheim
    • 2.13.1 Boehringer Ingelheim Details
    • 2.13.2 Boehringer Ingelheim Major Business
    • 2.13.3 Boehringer Ingelheim Oral Hypoglycemic Medications Product and Services
    • 2.13.4 Boehringer Ingelheim Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.14 Qilu Pharmaceutical
    • 2.14.1 Qilu Pharmaceutical Details
    • 2.14.2 Qilu Pharmaceutical Major Business
    • 2.14.3 Qilu Pharmaceutical Oral Hypoglycemic Medications Product and Services
    • 2.14.4 Qilu Pharmaceutical Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.15 Jiangsu Deyuan Pharmaceutical
    • 2.15.1 Jiangsu Deyuan Pharmaceutical Details
    • 2.15.2 Jiangsu Deyuan Pharmaceutical Major Business
    • 2.15.3 Jiangsu Deyuan Pharmaceutical Oral Hypoglycemic Medications Product and Services
    • 2.15.4 Jiangsu Deyuan Pharmaceutical Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Jiangsu Deyuan Pharmaceutical Recent Developments/Updates
  • 2.16 CTTQ
    • 2.16.1 CTTQ Details
    • 2.16.2 CTTQ Major Business
    • 2.16.3 CTTQ Oral Hypoglycemic Medications Product and Services
    • 2.16.4 CTTQ Oral Hypoglycemic Medications Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 CTTQ Recent Developments/Updates

3 Competitive Environment: Oral Hypoglycemic Medications by Manufacturer

  • 3.1 Global Oral Hypoglycemic Medications Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Oral Hypoglycemic Medications Revenue by Manufacturer (2021-2026)
  • 3.3 Global Oral Hypoglycemic Medications Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Oral Hypoglycemic Medications by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Oral Hypoglycemic Medications Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Oral Hypoglycemic Medications Manufacturer Market Share in 2025
  • 3.5 Oral Hypoglycemic Medications Market: Overall Company Footprint Analysis
    • 3.5.1 Oral Hypoglycemic Medications Market: Region Footprint
    • 3.5.2 Oral Hypoglycemic Medications Market: Company Product Type Footprint
    • 3.5.3 Oral Hypoglycemic Medications Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Oral Hypoglycemic Medications Market Size by Region
    • 4.1.1 Global Oral Hypoglycemic Medications Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Oral Hypoglycemic Medications Consumption Value by Region (2021-2032)
    • 4.1.3 Global Oral Hypoglycemic Medications Average Price by Region (2021-2032)
  • 4.2 North America Oral Hypoglycemic Medications Consumption Value (2021-2032)
  • 4.3 Europe Oral Hypoglycemic Medications Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Oral Hypoglycemic Medications Consumption Value (2021-2032)
  • 4.5 South America Oral Hypoglycemic Medications Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Oral Hypoglycemic Medications Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Oral Hypoglycemic Medications Sales Quantity by Type (2021-2032)
  • 5.2 Global Oral Hypoglycemic Medications Consumption Value by Type (2021-2032)
  • 5.3 Global Oral Hypoglycemic Medications Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Oral Hypoglycemic Medications Sales Quantity by Application (2021-2032)
  • 6.2 Global Oral Hypoglycemic Medications Consumption Value by Application (2021-2032)
  • 6.3 Global Oral Hypoglycemic Medications Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Oral Hypoglycemic Medications Sales Quantity by Type (2021-2032)
  • 7.2 North America Oral Hypoglycemic Medications Sales Quantity by Application (2021-2032)
  • 7.3 North America Oral Hypoglycemic Medications Market Size by Country
    • 7.3.1 North America Oral Hypoglycemic Medications Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Oral Hypoglycemic Medications Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Oral Hypoglycemic Medications Sales Quantity by Type (2021-2032)
  • 8.2 Europe Oral Hypoglycemic Medications Sales Quantity by Application (2021-2032)
  • 8.3 Europe Oral Hypoglycemic Medications Market Size by Country
    • 8.3.1 Europe Oral Hypoglycemic Medications Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Oral Hypoglycemic Medications Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Oral Hypoglycemic Medications Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Oral Hypoglycemic Medications Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Oral Hypoglycemic Medications Market Size by Region
    • 9.3.1 Asia-Pacific Oral Hypoglycemic Medications Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Oral Hypoglycemic Medications Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Oral Hypoglycemic Medications Sales Quantity by Type (2021-2032)
  • 10.2 South America Oral Hypoglycemic Medications Sales Quantity by Application (2021-2032)
  • 10.3 South America Oral Hypoglycemic Medications Market Size by Country
    • 10.3.1 South America Oral Hypoglycemic Medications Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Oral Hypoglycemic Medications Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Oral Hypoglycemic Medications Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Oral Hypoglycemic Medications Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Oral Hypoglycemic Medications Market Size by Country
    • 11.3.1 Middle East & Africa Oral Hypoglycemic Medications Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Oral Hypoglycemic Medications Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Oral Hypoglycemic Medications Market Drivers
  • 12.2 Oral Hypoglycemic Medications Market Restraints
  • 12.3 Oral Hypoglycemic Medications Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Oral Hypoglycemic Medications and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Oral Hypoglycemic Medications
  • 13.3 Oral Hypoglycemic Medications Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Oral Hypoglycemic Medications Typical Distributors
  • 14.3 Oral Hypoglycemic Medications Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Oral Hypoglycemic Medications market size was valued at US$ 76900 million in 2025 and is forecast to a readjusted size of US$ 135090 million by 2032 with a CAGR of 8.5% during review period.
    Oral Hypoglycemic Medications are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Oral Hypoglycemic Medications market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Oral Hypoglycemic Medications market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Oral Hypoglycemic Medications market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Oral Hypoglycemic Medications market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Oral Hypoglycemic Medications market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Oral Hypoglycemic Medications
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Oral Hypoglycemic Medications market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Merck, Novartis, Huadong Medicine, Sanofi, Novo Nordisk, Servier, Takeda Pharmaceutical, Luye Pharmaceutical, Taiji Group, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Oral Hypoglycemic Medications market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Biguanides
    Sulfonylureas
    Meglitinides
    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    SGLT2 Inhibitors
    Thiazolidinediones
    Alpha-Glucosidase Inhibitors
    Other
    Market segment by Application
    Hospital
    Clinic
    Other
    Major players covered
    Bayer
    Merck
    Novartis
    Huadong Medicine
    Sanofi
    Novo Nordisk
    Servier
    Takeda Pharmaceutical
    Luye Pharmaceutical
    Taiji Group
    CR Double-Crane
    AstraZeneca
    Boehringer Ingelheim
    Qilu Pharmaceutical
    Jiangsu Deyuan Pharmaceutical
    CTTQ
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Oral Hypoglycemic Medications product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Oral Hypoglycemic Medications, with price, sales quantity, revenue, and global market share of Oral Hypoglycemic Medications from 2021 to 2026.
    Chapter 3, the Oral Hypoglycemic Medications competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Oral Hypoglycemic Medications breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Oral Hypoglycemic Medications market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Oral Hypoglycemic Medications.
    Chapter 14 and 15, to describe Oral Hypoglycemic Medications sales channel, distributors, customers, research findings and conclusion.

    Buy now